Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

被引：80

作者：

Garcia-Guerrero, Estefania ^{[1
,2
]}

Gogishvili, Tea ^{[1
]}

Danhof, Sophia ^{[1
]}

Schreder, Martin ^{[1
]}

Pallaud, Celine ^{[3
]}

Perez-Simon, Jose Antonio ^{[2
]}

Einsele, Hermann ^{[1
]}

Hudecek, Michael ^{[1
]}

机构：

[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany

[2] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Seville, Spain

[3] Novartis Pharmaceut, Basel, Switzerland

来源：

BLOOD | 2017年 / 129卷 / 25期

关键词：

CLINICAL-EFFICACY; TARGETING CD38; MULTIPLE; DEXAMETHASONE; MONOTHERAPY; INHIBITORS; EXPRESSION; THERAPY; COMBINATION; BORTEZOMIB;

D O I：

10.1182/blood-2017-03-770776

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3386 / 3388

页数：3

共 20 条

[1] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors [J].

de Weers, Michel ;

Tai, Yu-Tzu ;

van der Veer, Michael S. ;

Bakker, Joost M. ;

Vink, Tom ;

Jacobs, Danielle C. H. ;

Oomen, Lukas A. ;

Peipp, Matthias ;

Valerius, Thomas ;

Slootstra, Jerry W. ;

Mutis, Tuna ;

Bleeker, Wim K. ;

Anderson, Kenneth C. ;

Lokhorst, Henk M. ;

van de Winkel, Jan G. J. ;

Parren, Paul W. H. I. .

JOURNAL OF IMMUNOLOGY, 2011, 186 (03) :1840-1848

[2] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[3] Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML [J].

Laszlo, George S. ;

Gudgeon, Chelsea J. ;

Harrington, Kimberly H. ;

Dell'Aringa, Justine ;

Newhall, Kathryn J. ;

Means, Gary D. ;

Sinclair, Angus M. ;

Kischel, Roman ;

Frankel, Stanley R. ;

Walter, Roland B. .

BLOOD, 2014, 123 (04) :554-561

[4] The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin [J].

Lemaire, Miguel ;

Fristedt, Charlotte ;

Agarwal, Prasoon ;

Menu, Eline ;

Van Valckenborgh, Els ;

De Bruyne, Elke ;

Osterborg, Anders ;

Atadja, Peter ;

Larsson, Olle ;

Axelson, Magnus ;

Van Camp, Ben ;

Jernberg-Wiklund, Helena ;

Vanderkerken, Karin .

CLINICAL CANCER RESEARCH, 2012, 18 (08) :2230-2239

[5] Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies [J].

Liu, H. B. ;

Urbanavicius, D. ;

Tan, P. ;

Spencer, A. ;

Dear, A. E. .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (04) :1742-1748

[6] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma [J].

Lokhorst, H. M. ;

Plesner, T. ;

Laubach, J. P. ;

Nahi, H. ;

Gimsing, P. ;

Hansson, M. ;

Minnema, M. C. ;

Lassen, U. ;

Krejcik, J. ;

Palumbo, A. ;

van de Donk, N. W. C. J. ;

Ahmadi, T. ;

Khan, I. ;

Uhlar, C. M. ;

Wang, J. ;

Sasser, A. K. ;

Losic, N. ;

Lisby, S. ;

Basse, L. ;

Brun, N. ;

Richardson, P. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13) :1207-1219

[7] Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial [J].

Lonial, Sagar ;

Weiss, Brendan M. ;

Usmani, Saad Z. ;

Singhal, Seema ;

Chari, Ajai ;

Bahlis, Nizar J. ;

Belch, Andrew ;

Krishnan, Amrita ;

Vescio, Robert A. ;

Victoria Mateos, Maria ;

Mazumder, Amitabha ;

Orlowski, Robert Z. ;

Sutherland, Heather J. ;

Blade, Joan ;

Scott, Emma C. ;

Oriol, Albert ;

Berdeja, Jesus ;

Gharibo, Mecide ;

Stevens, Don A. ;

LeBlanc, Richard ;

Sebag, Michael ;

Callander, Natalie ;

Jakubowiak, Andrzej ;

White, Darrell ;

de la Rubia, Javier ;

Richardson, Paul G. ;

Lisby, Steen ;

Feng, Huaibao ;

Uhlar, Clarissa M. ;

Khan, Imran ;

Ahmadi, Tahamtan ;

Voorhees, Peter M. .

LANCET, 2016, 387 (10027) :1551-1560

[8] Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma [J].

Lonial, Sagar ;

Dimopoulos, Meletios ;

Palumbo, Antonio ;

White, Darrell ;

Grosicki, Sebastian ;

Spicka, Ivan ;

Walter-Croneck, Adam ;

Moreau, Philippe ;

Mateos, Maria-Victoria ;

Magen, Hila ;

Belch, Andrew ;

Reece, Donna ;

Beksac, Meral ;

Spencer, Andrew ;

Oakervee, Heather ;

Orlowski, Robert Z. ;

Taniwaki, Masafumi ;

Roellig, Christoph ;

Einsele, Hermann ;

Wu, Ka Lung ;

Singhal, Anil ;

San-Miguel, Jesus ;

Matsumoto, Morio ;

Katz, Jessica ;

Bleickardt, Eric ;

Poulart, Valerie ;

Anderson, Kenneth C. ;

Richardson, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (07) :621-631

[9] The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance [J].

Maiso, Patricia ;

Carvajal-Vergara, Xonia ;

Ocio, Enrique M. ;

Lopez-Perez, Ricardo ;

Mateo, Gema ;

Gutierrez, Norma ;

Atadja, Peter ;

Pandiella, Atanasio ;

San Miguel, Jesus F. .

CANCER RESEARCH, 2006, 66 (11) :5781-5789

[10] Human CD38, a cell-surface protein with multiple functions [J].

Mehta, K ;

Shahid, U ;

Malavasi, F .

FASEB JOURNAL, 1996, 10 (12) :1408-1417

← 1 2 →